Drugs / EDP1815
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05682222 | Jun → Oct 2022 | — | Evelo Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05066373 | Aug 2021 → Aug 2022 | — | Evelo Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03733353 | Nov 2018 → Oct 2021 | atopic eczema, psoriasis | Evelo Biosciences, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05439941 | Jun 2022 → May 2023 | atopic eczema | Evelo Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05121480 | Jan 2022 → Mar 2023 | atopic eczema | Evelo Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04603027 | Sep 2020 → Jul 2021 | psoriasis | Evelo Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04488575 | Aug 2020 → May 2021 | COVID-19 | Evelo Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04393246 | Jul 2020 → Jun 2022 | COVID-19 | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP1815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04488575 ↗ |
| Modality | Other / unclassified | “EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor.” NCT04393246 ↗ |
| Route | Oral | “EDP1815 is an orally administered monoclonal microbial” NCT03733353 ↗ |